Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
WILMINGTON, Del., Feb. 05, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)?
- Did you purchase your shares between May 17, 2013 and December 28, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint (the “Complaint”) has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the common stock of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL) between May 17, 2013 and December 28, 2015, inclusive (the “Class Period”).
The Complaint alleges that the Company and certain of its officers and directors (“Defendants”) violated the Securities Exchange Act of 1934 by making materially false and misleading statements, and omitting material facts, about Anavex’s business, operations, and prospects.
According to the Complaint, Defendants misrepresented and/or failed to disclose that during the Class Period, the Company used a paid stock promoter to artificially inflate the price of Anavex stock. On December 29, 2015, the Company disclosed that it had been subpoenaed by the Securities and Exchange Commission in connection with “the recent unusual activity in the market for the Company’s shares.” On the day of that disclosure, the price of Anavex shares fell from a close of $7.03 per share to $6.29 per share. On the following day, December 30, 2015, Anavex’s stock price closed at $5.50 per share.
If you wish to serve as lead plaintiff, you must move the Court no later than February 29, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you suffered a loss in Anavex and would like to obtain additional information, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail at [email protected]; or at http://rigrodskylong.com/investigations/anavex-life-sciences-corp-avxl/.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
